Results 101 to 110 of about 14,494 (232)

Renal function change after switching tenofovir disoproxil fumarate for tenofovir alafenamide in the HIV-positive patients of a metropolitan sexual health service

AIDS Research and Therapy, 2019
Background Tenofovir disoproxil fumarate (TDF) is widely used in the management of HIV-infection, but has been associated with renal impairment in a small proportion of patients.
Dane Turner, Douglas Drak, Catherine C. O’Connor, David J. Templeton, David M. Gracey   +4 more
doaj   +1 more source

Osteopenia in a young man associated with the use of tenofovir disoproxil fumarate

Clinical Case Reports, 2022
Tenofovir disoproxil fumarate is a recommended first‐line therapy for patients with chronic hepatitis B, although the frequent Tenofovir disoproxil fumarate related adverse drug reactions are nephrotoxicity and bone toxicity.
Chunmei Li, Hui Li, Ming Gong, Jia Wei
doaj   +1 more source

Low-level viremia in nucleoside analog-treated chronic hepatitis B patients

Chinese Medical Journal, 2021
. Low-level viremia (LLV) was defined as persistent or intermittent episodes of detectable hepatitis B virus (HBV) DNA (
Qian Zhang, Da-Chuan Cai, Peng Hu, Hong Ren, Peng Lyu   +4 more
doaj   +1 more source

Evolving uses of oral reverse transcriptase inhibitors in the HIV-1 epidemic: From treatment to prevention [PDF]

, 2013
The HIV epidemic continues unabated, with no highly effective vaccine and no cure. Each new infection has significant economic, social and human costs and prevention efforts are now as great a priority as global antiretroviral therapy (ART) scale up ...
A Bedri, A Calmy, A Coovadia, A Coovadia, A De Luca, A Hill, A Kunz, A Moorthy, A Moorthy, A Shibata, A Zolopa, AN Phillips, AY Liu, BE Nichols, BE Nichols, BG Brenner, BR Yehia, C Laurent, C Pretorius, C Unge, C Unge, C Zeh, CA Boucher, CB Hurt, CJ Hoffmann, CL Townsend, CS Chasela, D Descamps, D Frentz, D Frentz, D Persaud, DA van de Vijver, DA van de Vijver, DADS Group, DAMC Van de vijver, David A M C Van de Vijver, DC Vissers, DE Bennett, DJ McColl, E Arrive, E Bendavid, E Mills, EM Connor, ER Cooper, ES Daar, F Doualla-Bell, F Tanser, F van Leth, F van Leth, FA Frankel, FDA, FJ Palella Jr, G Jourdain, G Jourdain, GL Melikian, GN Nikolenko, H Sunpath, HM Coovadia, I de Vincenzi, I Thior, J Bor, J Fogel, J Marrazzo, J Mermin, J Mermin, J Ren, J Vercauteren, JA Hontelez, JA McIntyre, JB Nachega, JE Gallant, JE Gallant, JM Baeten, JM Baeten, JM Fogel, JM Whitcomb, JO Kahn, Joint United Nations Programme on HIV/AIDS (UNAIDS), JW Eaton, KA Delviks-Frankenberry, KN Althoff, L Ryom, L Van Damme, L Wittkop, LA Guay, M Lallemant, M Mirochnick, MA Fischl, MA Thompson, MA Wainberg, Mark A Wainberg, MC Hosseinipour, MC Thigpen, MD Miller, MS Cohen, N Ford, N Shaffer, N Sood, NA Martinson, NA Wade, NE Mackie, NI Kumwenda, P Mugyenyi, PR Meyer, Q Abdool Karim, R Granich, R Gupta, R Kaplan, Ravindra K Gupta, RE Barth, RF Schinazi, RF Schinazi, RK Gupta, RK Gupta, RL Hamers, RL Hamers, RL Shapiro, RM Granich, RM Grant, RM Gulick, RM Mainardes, RS Veazey, S Lockman, S Loubser, S Rosen, S Staszewski, S Staszewski, S Sungkanuparph, S Yerly, SH Eshleman, SH Yap, Sheetal Manicklal, SL Spruance, T Flys, U CHIC, UL Abbas, UM Parikh, UNAIDS, UNAIDS, V Cambiano, V von Wyl, VD Lima, VS Gill, WHO, WHO, Z Shubber   +145 more
core   +4 more sources

Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, rando

The Lancet, 2021
BACKGROUND Antiretroviral therapy (ART) during pregnancy is important for both maternal health and prevention of perinatal HIV-1 transmission; however adequate data on the safety and efficacy of different ART regimens that are likely to be used by ...
S. Lockman, S. Brummel, L. Ziemba, L. Stranix-Chibanda, K. McCarthy, A. Coletti, P. Jean‐Philippe, Benjamin Johnston, Chelsea Krotje, L. Fairlie, R. Hoffman, P. Sax, S. Moyo, N. Chakhtoura, J. Stringer, G. Masheto, Violet Korutaro, H. Cassim, B. Mmbaga, E. Joao, S. Hanley, Lynette Purdue, Lewis B Holmes, J. Momper, R. Shapiro, Navdeep K. Thoofer, J. Rooney, L. Frenkel, K. R. Amico, L. Chinula, J. Currier, B. Best, Cheryl Blanchette, R. Browning, Yao Cheng, Andee Fox, Nagawa Jaliaah, Kevin C Knowles, M. Mirochnick, W. Murtaugh, Emmanuel Patras, Mauricio Pinilla, J. van Wyk, F. Whalen   +43 more
semanticscholar   +1 more source

Efficacy of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide in treatment-naive hepatitis B patients

Hepatology International, 2021
Antiviral agents for chronic hepatitis B (CHB) reduced the risk of hepatocellular carcinoma (HCC) development. The outcomes of entecavir (ETV), tenofovir disoproxil fumarate (TDF), and tenofovir alafenamide (TAF) were compared in patients with CHB.Between 2017 and 2019, treatment-naïve patients with CHB treated with ETV, TDF, and TAF were recruited ...
Hye Yeon Chon, Sang Hoon Ahn, Yoon Jun Kim, Jung-Hwan Yoon, Jeong-Hoon Lee, Dong Hyun Sinn, Seung Up Kim   +6 more
openaire   +3 more sources

HBV RNA Predicts the Risk of Off‐Treatment Relapse in Chronic Hepatitis B Patients With NAs Therapy: A Systematic Review and Meta‐Analysis

Journal of Viral Hepatitis, Volume 33, Issue 4, April 2026.
ABSTRACT Since there are currently few antiviral drugs that can effectively reduce hepatitis B surface antigen levels, the recurrence rate remains high in patients with chronic hepatitis B (CHB) after discontinuing nucleoside analogues (NAs) treatment.
Dong‐Hui Wang, Jia‐Lan Wang, Su‐Wen Jiang, Ai‐Wu Zhou, Meng‐Han Jin, Hao‐Jin Zhang, Shi‐Qi Yang, Shi‐Yang Fan, Ai‐Rong Hu   +8 more
wiley   +1 more source

Comparative effectiveness of dolutegravir + lamivudine versus three‐drug regimens in Swedish clinical practice: a nationwide study

Journal of the International AIDS Society, Volume 29, Issue 3, March 2026.
Abstract Introduction HIV guidelines recommend switching from a three‐drug regimen (3DR) to dolutegravir + lamivudine (DTG+3TC) for eligible individuals. This retrospective national cohort study used Swedish InfCareHIV registry data to evaluate long‐term outcomes of adults with HIV RNA <50 copies/ml who switched to DTG+3TC or a guideline‐recommended ...
Erik Sörstedt, George Nduva, Fredrik Månsson, Åsa Mellgren, Johanna Repits, Eva Fernvik, Adam Stubbs, Melanie Schroeder, Johanna Brännström, Christina Carlander   +9 more
wiley   +1 more source

Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety?

Journal of Virus Eradication, 2018
Background: Higher plasma tenofovir concentrations are associated with higher risks of renal and bone adverse events. The pharmacokinetic boosters ritonavir (RTV) and cobicistat (COBI) significantly increase plasma area under the curve (AUC ...
Andrew Hill, Sophie L. Hughes, Dzintars Gotham, Anton L. Pozniak   +3 more
doaj   +1 more source

Overcoming barriers, driving progress: Clinical science at IAS 2025

Journal of the International AIDS Society, Volume 29, Issue 3, March 2026.
Abstract Introduction The 13th IAS Conference on HIV Science, held in Kigali, Rwanda (13–17 July 2025), highlighted key advances in clinical research. Presentations focused on sustaining HIV treatment and prevention amid financial constraints, innovations in long‐acting oral antiretrovirals, and the management of comorbidities and co‐infections ...
Ezequiel Cordova, Simiso Sokhela, Jasmini Alagaratnam, Juan Ambrosioni   +3 more
wiley   +1 more source